Compare LyondellBasell Industries NV (LYB) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Nuwellis Inc — how do they compare? LyondellBasell Industries NV trades at $61.36 (market cap $19.60B), while Nuwellis Inc trades at $2.9 (market cap $1.09M). The key difference: LyondellBasell Industries NV is far larger — about 17981.7× Nuwellis Inc's market cap, and LyondellBasell Industries NV pays a 6.78% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| LYB | NUWE | |
|---|---|---|
Market Cap | $19.60B | $1.09M |
Sector | Basic Materials | Technology |
52-Week High | $82.38 | $527.46 |
52-Week Low | $42.28 | $2.80 |
Enterprise Value | $31.22B | -$722.58K |
Dividend Yield | 6.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYB trades at $60.78, up 2.69% today, with a bullish technical signal driven by moving averages. The stock shows mixed fundamentals: revenue declined to $30.15B in 2025 with a net loss of $745M, yet valuation ratios like P/S of 0.64 appear attractive. Recent news highlights partnerships for sustainable packaging, while cash flow remains positive. Analysts are divided with a consensus price target of $73.11, suggesting 20% upside potential from current levels.
Outlook: LYB offers value appeal with low P/S and dividend yield, but faces profitability challenges and industry headwinds. Risks include volatile earnings and high debt. The stock is suitable for value investors tolerant of cyclical downturns, with catalysts from restructuring and sustainability initiatives.
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
